ICAM1 and cancer: In a meta-analysis of 18 case-control studies, ICAM-1 polymorphism was linked to cancer risk [376], similar to a meta-analysis of 12 case-control studies on T2D [377] and CHD in a meta-analysis of 11 case-control studies [378].